October 16, 2006 — The European Commission has approved pregabalin capsules for the treatment of central neuropathic pain associated with spinal cord injury, stroke, and multiple sclerosis; and ...

ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher ...

HORSHAM, PA and KENILWORTH, NJ, NOVEMBER 6, 2007—Centocor, Inc., Schering-Plough Corporation, and Mitsubishi Tanabe Pharma Corporation announced today that an estimated one million patients have now ...

May 15, 2006 — Health Canada has approved a 500-mg tablet formulation of saquinavir mesylate that significantly reduces the daily pill count for patients with HIV; the European Commission has approved ...

Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, according to research ...

Johnson & Johnson's big-selling Remicade has held most of its ground against biosimilar competition, thanks in part to some aggressive payer contracts that rivals—including Pfizer—have called into ...

A second biosimilar to infliximab, marketed as Remicade by Johnson & Johnson, has received FDA approval. Infliximab-abda (Renflexis) was developed by Samsung Bioepis/Merck and has been approved for ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. After previously discontinuing infliximab, 35% of ...

After the first biosimilar of Johnson & Johnson’s big-selling immunology drug Remicade hit the market last year at a modest discount, another has come along with a much deeper pricing slash. Samsung ...

Hidradenitis suppurativa (HS) is a difficult-to-treat skin condition that has responded to infliximab, although payer support in this setting is often lacking. Investigators have reported equivalent ...